Clovis Oncology Inc. (CLVS) Is Rising On FDA Breakthrough Designation

Shutterstock photo

(RTTNews.com) - Clovis Oncology Inc. ( CLVS ) announced Tuesday morning that it has been granted Breakthrough Therapy designation from the FDA for Rubraca, a prostate cancer treatment.

Clovis Oncology gapped open sharply higher this morning and is now up 4.62 at $33.76 on above average volume. The stock has climbed to over a 2-week high.

Read the original article on RTTNews (http://www.rttnews.com/2940206/clovis-oncology-inc-clvs-is-rising-on-fda-breakthrough-designation.aspx)

For comments and feedback: contact editorial@rttnews.com

This article appears in: Stocks
Referenced Symbols: CLVS

More from RTT News


See All RTT news

Research Brokers before you trade

Want to trade FX?